bepridil has been researched along with Kidney Failure, Chronic in 3 studies
Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.
bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " These products are well absorbed from the gastrointestinal tract but undergo variable degrees of transformation during the first passage through the liver." | 2.37 | [Clinical pharmacology of calcium inhibitors]. ( Martre, H; Singlas, E; Taburet, AM, 1985) |
| " Thus, no dosage adjustment will be required for ESRD patients and those receiving hemodialysis with cuprophane filters." | 1.29 | Pharmacokinetics of bepridil and two of its metabolites in patients with end-stage renal disease. ( Awni, WM; Desiraju, RK; Halstenson, CE; Matzke, GR; Minn, FL; Nayak, RK; Opsahl, JA, 1995) |
| "The effects of end-stage renal disease (ESRD) and hemodialysis on the in vitro plasma protein binding of bepridil hydrochloride were investigated." | 1.29 | Effects of hemodialysis on plasma protein binding of bepridil. ( Halstenson, CE; Matzke, GR; Nayak, RK; Opsahl, JA; Pritchard, JF, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Awni, WM | 1 |
| Halstenson, CE | 2 |
| Nayak, RK | 2 |
| Opsahl, JA | 2 |
| Desiraju, RK | 1 |
| Minn, FL | 1 |
| Matzke, GR | 2 |
| Pritchard, JF | 1 |
| Singlas, E | 1 |
| Martre, H | 1 |
| Taburet, AM | 1 |
1 review available for bepridil and Kidney Failure, Chronic
| Article | Year |
|---|---|
[Clinical pharmacology of calcium inhibitors].
Topics: Age Factors; Animals; Bepridil; Biological Availability; Biotransformation; Calcium Channel Blockers | 1985 |
2 other studies available for bepridil and Kidney Failure, Chronic
| Article | Year |
|---|---|
Pharmacokinetics of bepridil and two of its metabolites in patients with end-stage renal disease.
Topics: Administration, Oral; Adult; Bepridil; Female; Humans; Kidney Failure, Chronic; Middle Aged; Renal D | 1995 |
Effects of hemodialysis on plasma protein binding of bepridil.
Topics: Adult; Bepridil; Blood Proteins; Creatinine; Female; Humans; Kidney Failure, Chronic; Middle Aged; O | 1995 |